Equity Risk Analysis

Zevra Therapeutics relies entirely on MIPLYFFA, its sole approved rare disease treatment, creating concentration risk that depresses valuation multiples versus diversified biotech peers. Any regulatory action against the drug would eliminate revenue. Single-product commercial-stage biotechs typically trade at 50-80% discounts to multi-asset competitors.

Copa Holdings, S.A. (NYSE: CPA) operates one of Latin America's most efficient airline networks, but its near-total reliance on Panama City's Tocumen International Airport as a central hub creates a structural vulnerability that equity investors may be underpricing. A single disruptive event at Tocumen — whether weather, infrastructure failure, or air traffic control breakdown — could cascade across the airline's entire regional network. With catastrophic-severity risk and a 70% confidence asses